Evidence map›Paper›PMID 39937301›Full record

ArticleDiscover oncology2025

Inhibition of hemangioma development by regulating the VEGF/VEGFR autocrine loop via the miR-494/PTEN pathway.

Jingyu Peng, Feifei Li, Mingke Qiu, Xinjie Xu, Guanghua Liu, Jingmin Ou

Abstract read
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingyu Peng *Department of Intervention and Vascular Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medcine, 1665 Kongjiang Road, Yangpu District, Shanghai, China.
Feifei Li *Department of Health Vascular Surgery and Intervention, Chongming Hospital Affiliated to Shanghai University of Medicine and Health Sciences, Shanghai, China.
Mingke QiuDepartment of Intervention and Vascular Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medcine, 1665 Kongjiang Road, Yangpu District, Shanghai, China.
Xinjie XuDepartment of Intervention and Vascular Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medcine, 1665 Kongjiang Road, Yangpu District, Shanghai, China.
Guanghua LiuDepartment of Intervention and Vascular Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medcine, 1665 Kongjiang Road, Yangpu District, Shanghai, China.
Jingmin OuDepartment of Intervention and Vascular Surgery, XinHua Hospital, Shanghai Jiaotong University School of Medcine, 1665 Kongjiang Road, Yangpu District, Shanghai, China. oujingmin@xinhuamed.com.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfantile hemangioma (IH) is the most common type of benign vascular tumor found in infants and young children. Hemangioma-derived endothelial cells within the lesion from birth to three months of age are the primary characteristic of IH. (hemangioma-derived endothelial cells, HemECs) proliferated rapidly and formed hemangioma masses, most of which gradually regressed spontaneously within the next 1 to 5 years of age and continued to improve until the age of 6 to 12 years. But 10-15% of IH cases can still result in ulcerative, obstructive, deformity, and even potentially fatal consequences and sequelae. These conditions seriously affect children's physical and mental health as well as their growth and development, necessitating prompt and efficient medical attention of IH is known.

objectiveThe purpose of this work. HemECs are crucial to the development of IH as a result. Not all of the pathophwork is to examine the impact of OMT on HemECs, with a specific emphasis on its role in cell migration, proliferation, cell cycle regulation, and apoptosis. Additionally, we will research the influence of OMT on the VEGFA/VEGFR-2 signaling pathway in HemECs and assess the impact of OMT on the miR-494/PTEN axis.

methodsThe Cell Counting Kit-8 (CCK-8) assay was employed to evaluate the influence of Oxymatrine (OMT) on the proliferation of Hemangioma Endothelial Cells (HemECs). The Transwell Assay was employed to detect cell invasion and migration. The cell cycle and apoptosis were analyzed through flow cytometry. The impact of OMT on the expression of apoptosis markers (cleaved caspase-3) and proteins associated with the cell cycle (Cyclin D1, Bcl-2, Bax) was examined using Western Blot and Reverse Transcription Polymerase Chain Reaction (RT-PCR).

resultsOMT treatment significantly inhibited the proliferation of HemECs, especially when combined with the miR-494 inhibitor. Additionally, OMT administration raised the proportion of cells entering the G2 phase, accelerated apoptosis, and decreased HemECs' capacity for migration and invasion. The results of Western Blot and RT-PCR demonstrated that OMT decreased the expression levels of Bax and Cleaved Caspase-3 while increasing the expression of Bcl-2 and Cyclin D1. OMT and miR-494 inhibitors have distinct impacts on the phosphorylated versions of VEGFR-2, PTEN, and ERK signaling pathways. OMT may control cell survival and proliferation through the miR-494/PTEN pathway, as evidenced by the fact that PTEN expression was dramatically upregulated in the miR-1297 inhibitor with OMT treatment group, while p-ERK expression was markedly reduced in that group.

conclusionsOMT effectively inhibits the growth, migration, and apoptosis of hemangioma endothelial cells, likely by regulating key proteins involved in the cell cycle and apoptosis. The combination with miR-494 inhibitors enhances its therapeutic effect, suggesting a potential new approach for hemangioma treatment. These findings support the development of OMT-based strategies for hemangiomas and its potential use in cancer therapy.

Indexed as

HemangiomamiR-494OxymatrineVEGFVEGFR autocrine loop

Identifiers

PMID39937301
PMCPMC11822158

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.